67 completed, 5 recruiting, 4 unknown, 1 terminated. 39 Phase 1, 19 Phase 4, 5 Not applicable, 5 Phase 3, 3 Phase 2.
Follow repaglinide: new trials by email Literature Review of repaglinide trials Research Report on repaglinide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult Subjects Fosmanogepix, Placebo, The medicine cocktail (caffeine, bupropion, flurbiprofen, omeprazole, dextromethorphan and midazolam) - Healthy Adult Participants | Phase 1 | Recruiting | Basilea Pharmaceutica | 42 | 2026-10-01 | 2026-10-19 |
| A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies pelabresib, repaglinide, midazolam - Advanced Malignancies | Phase 1 | Recruiting | Novartis Pharmaceuticals | 24 | 2026-06-12 | 2026-10-09 |
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. metformin hydrochloride 500 mg tablet, rosuvastatin 10 mg tablet, repaglinide 0.5 mg tablet - TP53 Y220C Mutation, Advanced Solid Tumors | Phase 1 | Recruiting | PMV Pharmaceuticals, Inc | 14 | 2026-02-04 | 2026-08-12 |
| Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants Vorasidenib, Bupropion, Flurbiprofen - Healthy Adult Participants | Phase 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | 28 | 2025-10-07 | 2026-02-17 |
| A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects Drug: VCT220, Repaglinide, Rosuvastatin, and Digoxin - Obesity &Amp; Overweight | Phase 1 | Completed | Vincentage Pharma Co., Ltd | 24 | 2025-07-01 | 2026-03-31 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Verastem, Inc. | 616 | 2025-06-24 | 2026-10-15 |
| A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants AZD5004, Rosuvastatin, Erythromycin - Healthy Participants | Phase 1 | Completed | AstraZeneca | 49 | 2025-05-06 | 2025-10-10 |
| A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects. Repaglinide, Atorvastatin, Digoxin - Healthy Adult Subject, Overweight Subject | Phase 1 | Unknown | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 30 | 2024-10-01 | 2024-09-23 |
| KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism Caffeine Tablet, Bupropion Hydrochloride Capsels, Repaglinide Capsels - Drug Interaction | Not applicable | Completed | Helsinki University Central Hospital | 12 | 2024-08-22 | 2026-03-06 |
| A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body zongertinib, midazolam, omeprazole - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 16 | 2024-07-30 | 2025-12-02 |
| A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants LY4100511 (DC-853) Dose 1, LY4100511 (DC-853) Dose 2, LY4100511 (DC-853) Dose 3 - Healthy | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 49 | 2024-07-16 | 2025-01-24 |
| A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood BI 1569912, Repaglinide, Midazolam - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 18 | 2024-05-15 | 2026-05-22 |
| A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults Midazolam, Repaglinide, TAK-279 - Healthy Volunteers | Phase 1 | Completed | Takeda | 20 | 2024-03-29 | 2024-05-23 |
| PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval repaglinide; midazolam; SHR4640, repaglinide; midazolam; SHR4640; SHR4640 placebo, repaglinide; midazolam; SHR4640 placebo - Gout and Hyperuricemia | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2024-01-04 | 2024-03-06 |
| A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants DC-806, Midazolam, Repaglinide - Healthy Participants | Phase 1 | Completed | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | 28 | 2023-10-16 | 2026-10-19 |
| Voxelotor CYP and Transporter Cocktail Interaction Study Voxelotor, Bupropion, Repaglinide - Sickle Cell Disease | Phase 1 | Completed | Pfizer | 44 | 2023-04-17 | 2024-11-22 |
| A Drug Interaction Study of LY3871801 in Healthy Participants LY3871801, Methotrexate, Warfarin - Healthy | Phase 1 | Completed | Eli Lilly and Company | 39 | 2022-11-02 | 2023-04-18 |
| A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers SHR0302 Tablets, Midazolam Maleate Tablets, Warfarin Sodium Tablets - Rheumatoid Arthritis | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2022-07-15 | 2022-12-22 |
| A Study of Imlunestrant (LY3484356) in Female Healthy Participants Imlunestrant, Repaglinide, Omeprazole - Healthy | Phase 1 | Completed | Eli Lilly and Company | 113 | 2022-07-07 | 2025-12-12 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib ATR-002, Placebo, Repaglinide - Healthy | Phase 1 | Completed | Atriva Therapeutics GmbH | 96 | 2022-06-23 | 2023-08-01 |
Showing 20 of 78. Sign in to see all of them.
Diabetes Mellitus, Type 2 (36) · Diabetes Mellitus (30) · Cystic Fibrosis (4) · Neoplasm Metastasis (2) · Obesity (2) · Pancreatic Neoplasms (2) · Anemia, Sickle Cell (1) · Appendiceal Neoplasms (1) · Arthritis, Rheumatoid (1) · Atherosclerosis (1) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Diseases (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1)
Novo Nordisk A/S (22) · Jiangsu HengRui Medicine Co., Ltd. (5) · Eli Lilly and Company (4) · Boehringer Ingelheim (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (2) · Novartis Pharmaceuticals (2) · Steno Diabetes Center Copenhagen (2) · Abliva AB (1) · Arbelaez, Ana Maria (1) · Astellas Pharma Europe B.V. (1) · Astellas Pharma Global Development, Inc. (1) · AstraZeneca (1) · Atriva Therapeutics GmbH (1) · Basilea Pharmaceutica (1)
United States (25) · China (19) · Canada (7) · United Kingdom (6) · Germany (5) · Italy (5) · Belgium (4) · South Korea (4) · France (3) · Spain (3) · Taiwan (3) · Australia (2) · Denmark (2) · Malaysia (2) · Netherlands (2)
Pierre Ernst, MD, MSc (3) · Alex Vo, PhD (1) · Allan A Vaag, M. D., Chief Physician (1) · Allan A Vaag, M.D. Chief Physician (1) · Andrea Kelly, MD (1) · Antoinette Moran, MD (1) · Chunlin Li, M.D&Ph.D (1) · Deepak Bhamidipati, MD (1) · Denise Simons-Morton, MD, PhD (1)
PMID 15983336, PMID 18539917, PMID 18666804, PMID 19476470, PMID 19531054, PMID 19592632, PMID 19898642, PMID 19900993, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 21366473, PMID 21663644, PMID 21780853, PMID 21958949, PMID 22019270, PMID 22049171, PMID 22179956, PMID 22374637, PMID 22432114, PMID 22450889, PMID 22515638, PMID 22619083, PMID 22646230, PMID 22723577, PMID 23033246, PMID 23238658, PMID 23412077, PMID 23809507, PMID 23990163, PMID 24170759, PMID 24296848, PMID 24493100, PMID 24595629, PMID 24620855, PMID 24779562, PMID 25088437, PMID 25127725, PMID 25159234, PMID 25172198, PMID 25193529, PMID 25229335, PMID 25267796, PMID 25652389
2023 (3), 2025 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), P60DK020579 (1)